Wierzbicki AS - Search Results

1

Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias.

Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Wierzbicki AS, et al. Curr Med Res Opin. 2005 Mar;21(3):333-8. doi: 10.1185/030079905X28872. Curr Med Res Opin. 2005. PMID: 15811200 Clinical Trial.

2

Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.

Wierzbicki AS, Reynolds TM, Crook MA. Wierzbicki AS, et al. Am J Cardiol. 2002 Jan 15;89(2):229-31. doi: 10.1016/s0002-9149(01)02208-1. Am J Cardiol. 2002. PMID: 11792350 No abstract available.

3

The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E.

Newman P, Bonello F, Wierzbicki AS, Lumb P, Savidge GF, Shearer MJ. Newman P, et al. Among authors: wierzbicki as. J Bone Miner Res. 2002 Mar;17(3):426-33. doi: 10.1359/jbmr.2002.17.3.426. J Bone Miner Res. 2002. PMID: 11874234 Free article.

4

Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus.

Christ ER, Carroll PV, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL. Christ ER, et al. Among authors: wierzbicki as. Am J Physiol Endocrinol Metab. 2002 May;282(5):E1154-62. doi: 10.1152/ajpendo.00470.2001. Am J Physiol Endocrinol Metab. 2002. PMID: 11934682 Free article. Clinical Trial.

5

Beyond LDL-C--the importance of raising HDL-C.

Wierzbicki AS, Mikhailidis DP. Wierzbicki AS, et al. Curr Med Res Opin. 2002;18(1):36-44. doi: 10.1185/030079902125000165. Curr Med Res Opin. 2002. PMID: 11999145 Review.

6

Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.

Wierzbicki AS, Mikhailidis DP. Wierzbicki AS, et al. Int J Cardiol. 2002 Jul;84(1):53-7. doi: 10.1016/s0167-5273(02)00118-3. Int J Cardiol. 2002. PMID: 12104065

7

The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter.

Wierzbicki AS, Hardman TC, Cheung J, Lambert-Hammill M, Patel S, Morrish Z, Lumb PJ, Lant AF. Wierzbicki AS, et al. Am J Hypertens. 2002 Jul;15(7 Pt 1):633-7. doi: 10.1016/s0895-7061(02)02927-8. Am J Hypertens. 2002. PMID: 12118912

8

Statin therapy in people with diabetes and high-risk patients.

Wierzbicki AS. Wierzbicki AS. Hosp Med. 2003 Jan;64(1):16-9. doi: 10.12968/hosp.2003.64.1.1838. Hosp Med. 2003. PMID: 12572329 Review.

9

The lipid and non-lipid effects of statins.

Wierzbicki AS, Poston R, Ferro A. Wierzbicki AS, et al. Pharmacol Ther. 2003 Jul;99(1):95-112. doi: 10.1016/s0163-7258(03)00055-x. Pharmacol Ther. 2003. PMID: 12804701 Review.

10

New lipid-lowering agents.

Wierzbicki AS. Wierzbicki AS. Expert Opin Emerg Drugs. 2003 Nov;8(2):365-76. doi: 10.1517/14728214.8.2.365. Expert Opin Emerg Drugs. 2003. PMID: 14661995 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters